| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients TT Batchelor, AG Sorensen, E di Tomaso, WT Zhang, DG Duda, ... Cancer cell 11 (1), 83-95, 2007 | 2134 | 2007 |
| Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. WA Banks, L Ortiz, SR Plotkin, AJ Kastin The Journal of pharmacology and experimental therapeutics 259 (3), 988-996, 1991 | 598 | 1991 |
| Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme DA Reardon, KL Fink, T Mikkelsen, TF Cloughesy, A O'Neill, S Plotkin, ... Journal of clinical oncology 26 (34), 5610-5617, 2008 | 593 | 2008 |
| Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma TT Batchelor, DG Duda, E di Tomaso, M Ancukiewicz, SR Plotkin, ... Journal of Clinical Oncology 28 (17), 2817-2823, 2010 | 585 | 2010 |
| Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation E Legius, L Messiaen, P Wolkenstein, P Pancza, RA Avery, Y Berman, ... Genetics in Medicine 23 (8), 1506-1513, 2021 | 565 | 2021 |
| Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 SR Plotkin, AO Stemmer-Rachamimov, FG Barker, C Halpin, TP Padera, ... New England Journal of Medicine 361 (4), 358-367, 2009 | 561 | 2009 |
| Diagnostic criteria for schwannomatosis M MacCollin, EA Chiocca, DG Evans, JM Friedman, R Horvitz, D Jaramillo, ... Neurology 64 (11), 1838-1845, 2005 | 468 | 2005 |
| Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation TT Batchelor, ER Gerstner, KE Emblem, DG Duda, J Kalpathy-Cramer, ... Proceedings of the national academy of sciences 110 (47), 19059-19064, 2013 | 391 | 2013 |
| NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth MF James, S Han, C Polizzano, SR Plotkin, BD Manning, ... Molecular and cellular biology 29 (15), 4250-4261, 2009 | 354 | 2009 |
| Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial A El-Jawahri, LM Podgurski, AF Eichler, SR Plotkin, JS Temel, SL Mitchell, ... Journal of Clinical Oncology 28 (2), 305-310, 2010 | 300 | 2010 |
| Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma TJ Kaley, P Wen, D Schiff, K Ligon, S Haidar, S Karimi, AB Lassman, ... Neuro-oncology 17 (1), 116-121, 2015 | 296 | 2015 |
| Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients SR Plotkin, VL Merker, C Halpin, D Jennings, MJ McKenna, GJ Harris, ... Otology & Neurotology 33 (6), 1046-1052, 2012 | 254 | 2012 |
| Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma C Lu-Emerson, M Snuderl, ND Kirkpatrick, J Goveia, C Davidson, ... Neuro-oncology 15 (8), 1079-1087, 2013 | 249 | 2013 |
| Treatment of relapsed central nervous system lymphoma with high-dose methotrexate SR Plotkin, RA Betensky, FH Hochberg, SA Grossman, GJ Lesser, ... Clinical cancer research 10 (17), 5643-5646, 2004 | 245 | 2004 |
| Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization as mode of escape E di Tomaso, M Snuderl, WS Kamoun, DG Duda, PK Auluck, L Fazlollahi, ... Cancer research 71 (1), 19-28, 2011 | 231 | 2011 |
| Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes CJ Farrell, SR Plotkin Neurologic clinics 25 (4), 925-946, 2007 | 228 | 2007 |
| Clinical features of schwannomatosis: a retrospective analysis of 87 patients VL Merker, S Esparza, MJ Smith, A Stemmer-Rachamimov, SR Plotkin The oncologist 17 (10), 1317-1322, 2012 | 227 | 2012 |
| Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844–848 M Koczkowska, Y Chen, T Callens, A Gomes, A Sharp, S Johnson, ... The American Journal of Human Genetics 102 (1), 69-87, 2018 | 225 | 2018 |
| Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria SR Plotkin, JO Blakeley, DG Evans, CO Hanemann, TJM Hulsebos, ... American journal of medical genetics Part A 161 (3), 405-416, 2013 | 200 | 2013 |
| Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis SR Plotkin, MA Bredella, W Cai, A Kassarjian, GJ Harris, S Esparza, ... PloS one 7 (4), e35711, 2012 | 178 | 2012 |